Purpose To assess the efficacy of 0.5 mg conbercept treatment in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Methods Randomized, double-masked, multicenter, sham-controlled phase Ⅲ clinical trial.Patients (≥ 50 years) with CNV secondary to AMD with lesion sizes of 12 disc areas or less and best-corrected visual acuity (BCVA) letter score of between 73 and19 were enrolled.Eligible patients were randomized 2:1 to conbercept treatment group and sham injection group.During the 3-month loading phase, conbercept group received intravitreal injection of conbercept 0.5mg monthly for 3 times; sham group received sham injection monthly for 3 times.Then during the followed maintenance phase till month 12, conbercept group received intravitreal injection of conbercept every 3 months; sham group received intravitreal injection of conbercept monthly for 3 times, followed by every 3 months to month 12 as well.